Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Haitao Gu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5122307210. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 8

  1. Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. Co-author DOI 10.1016/j.isci.2025.112509↗
  2. AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. Co-author DOI 10.3389/fonc.2025.1667445↗
  3. Targeting OAS3 for reversing M2d infiltration and restoring anti-tumor immunity in pancreatic cancer. Co-author DOI 10.1007/s00262-024-03898-w↗
  4. Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips. Co-author DOI 10.1016/j.isci.2022.105723↗
  5. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. First author DOI 10.1186/s12885-023-11239-w↗
  6. Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). Co-author DOI 10.1016/j.yexcr.2022.113402↗
  7. Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/atm-22-407↗
  8. NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/tlcr-22-311↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhengjun Qiu · 3 shared papers, 2022–2024 · strength 0.56
  2. Jiuliang Yan · 3 shared papers, 2022–2025 · strength 0.55
  3. Chuntao Wu · 3 shared papers, 2022–2025 · strength 0.55
  4. Zengya Guo · 2 shared papers, 2022–2023 · strength 0.35
  5. Yuhan Yang · 2 shared papers, 2022–2023 · strength 0.35
  6. Beiyuan Hu · 2 shared papers, 2022–2023 · strength 0.30
  7. Jiang Long · 2 shared papers, 2022–2023 · strength 0.30
  8. Jiang Long · 1 shared paper, 2025 · strength 0.26
  9. Qi Li · 1 shared paper, 2025 · strength 0.25
  10. Jingyi Zhou · 1 shared paper, 2025 · strength 0.25
  11. Chuan Liu · 1 shared paper, 2025 · strength 0.25
  12. Long Jiang · 1 shared paper, 2025 · strength 0.25
  13. Shaopeng Zhang · 1 shared paper, 2024 · strength 0.21
  14. Kunihiro Tsuchida · 1 shared paper, 2022 · strength 0.16
  15. Vishal Girishchandra Shelat · 1 shared paper, 2022 · strength 0.16
  16. Zhaowen Wang · 1 shared paper, 2022 · strength 0.16
  17. Chen Huang · 1 shared paper, 2023 · strength 0.16
  18. Peng Cao · 1 shared paper, 2023 · strength 0.16
  19. Xuan Han · 1 shared paper, 2023 · strength 0.16
  20. Qiongzhu Dong · 1 shared paper, 2022 · strength 0.15
  21. Xu Wang · 1 shared paper, 2023 · strength 0.15
  22. Lei Wang · 1 shared paper, 2023 · strength 0.15
  23. Qi Zhang · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.